Synergistic Effects of Azithromycin and STING Agonist Promote IFN-I Production by Enhancing the Activation of STING-TBK1 Signaling

References

• Ali S, Mann-Nüttel R, Schulze A, Richter L, Alferink J, Scheu S. Sources of type I interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver’s seat. Front Immunol. 2019;10:778. doi:10.3389/fimmu.2019.00778
   PubMed Web of Science ®Google Scholar
• Murira A, Lamarre A. Type-I interferon responses: from friend to foe in the battle against chronic viral infection. Front Immunol. 2016;7:609. doi:10.3389/fimmu.2016.00609
   PubMed Web of Science ®Google Scholar
• Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25(3):373–381. doi:10.1016/j.immuni.2006.08.007
   PubMed Web of Science ®Google Scholar
• Melissa N, Sarah J, Rachel K, et al. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med. 2022;9(1):e000625. doi:10.1136/lupus-2021-000625
   PubMed Web of Science ®Google Scholar
• Psarras A, Emery P, Vital EM. Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology. 2017;56(10):1662–1675. doi:10.1093/rheumatology/kew431
   PubMed Web of Science ®Google Scholar
• Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol. 2011;32(12):574–581. doi:10.1016/j.it.2011.08.004
   PubMed Web of Science ®Google Scholar
• Lukhele S, Boukhaled GM, Brooks DG. Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Semin Immunol. 2019;43:101277. doi:10.1016/j.smim.2019.05.001
   PubMed Web of Science ®Google Scholar
• Zahid A, Ismail H, Li B, Jin T. Molecular and structural basis of DNA sensors in antiviral innate immunity. Front Immunol. 2020;11:613039. doi:10.3389/fimmu.2020.613039
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386. doi:10.1038/nri1604
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061. doi:10.3389/fimmu.2018.02061
   PubMed Web of Science ®Google Scholar
• Ashley CL, Abendroth A, McSharry BP, Slobedman B. Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression. Viruses. 2019;11(3):246. doi:10.3390/v11030246
   PubMed Web of Science ®Google Scholar
• Park A, Iwasaki A. Type I and type III interferons – induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–878. doi:10.1016/j.chom.2020.05.008
   PubMed Web of Science ®Google Scholar
• Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469. doi:10.1038/s41586-020-2588-y
   PubMed Web of Science ®Google Scholar
• Heidary M, Ebrahimi Samangani A, Kargari A, et al. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. J Clin Lab Anal. 2022;36(6):e24427. doi:10.1002/jcla.24427
   PubMed Web of Science ®Google Scholar
• Jednačak T, Mikulandra I, Novak P. Advanced methods for studying structure and interactions of macrolide antibiotics. Int J Mol Sci. 2020;21(20):7799. doi:10.3390/ijms21207799
   PubMed Web of Science ®Google Scholar
• Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006;350(4):977–982. doi:10.1016/j.bbrc.2006.09.132
   PubMed Web of Science ®Google Scholar
• Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa b and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr Res. 2007;62(4):483–488. doi:10.1203/PDR.0b013e318142582d
   PubMed Web of Science ®Google Scholar
• Wang J, Chen Q, Zhang Z, et al. Azithromycin alleviates systemic lupus erythematosus via the promotion of M2 polarisation in lupus mice. Cell Death Discov. 2021;7(1):82. doi:10.1038/s41420-021-00466-4
   PubMed Web of Science ®Google Scholar
• Wang J, Xie L, Wang S, Lin J, Liang J, Xu J. Azithromycin promotes alternatively activated macrophage phenotype in systematic lupus erythematosus via PI3K/Akt signaling pathway. Cell Death Dis. 2018;9(11):1080. doi:10.1038/s41419-018-1097-5
   PubMedGoogle Scholar
• Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646–654. doi:10.1183/09031936.00095809
   PubMed Web of Science ®Google Scholar
• Li C, Zu S, Deng YQ, et al. Azithromycin protects against zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019;63(12):e00394–19. doi:10.1128/AAC.00394-19
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Haydar D, Abdel-Latif A, et al. Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19. Front Immunol. 2021;12:574425. doi:10.3389/fimmu.2021.574425
   PubMed Web of Science ®Google Scholar
• Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifirò G. Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. 2020;43(8):691–698. doi:10.1007/s40264-020-00976-7
   PubMed Web of Science ®Google Scholar
• Kournoutou GG, Dinos G. Azithromycin through the lens of the COVID-19 treatment. Antibiotics. 2022;11(8):1063. doi:10.3390/antibiotics11081063
   Google Scholar
• Khezri MR, Zolbanin NM, Ghasemnejad-berenji M, Jafari R. Azithromycin: immunomodulatory and antiviral properties for SARS-CoV-2 infection. Eur J Pharmacol. 2021;905:174191. doi:10.1016/j.ejphar.2021.174191
   PubMed Web of Science ®Google Scholar
• Oliver ME, Hinks TSC. Azithromycin in viral infections. Rev Med Virol. 2021;31(2):e2163. doi:10.1002/rmv.2163
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature. 2009;461(7265):788–792. doi:10.1038/nature08476
   PubMed Web of Science ®Google Scholar
• Zhang C, Shang G, Gui X, Zhang X, X-c B, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019;567(7748):394–398. doi:10.1038/s41586-019-1000-2
   PubMed Web of Science ®Google Scholar
• Yum S, Li M, Fang Y, Chen ZJ. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. Proc Natl Acad Sci U S A. 2021;118(14):e2100225118. doi:10.1073/pnas.2100225118
   PubMed Web of Science ®Google Scholar
• Ahn J, Barber GN. STING signaling and host defense against microbial infection. Exp Mol Med. 2019;51(12):1–10. doi:10.1038/s12276-019-0333-0
   Google Scholar
• Singh RS, Vidhyasagar V, Yang S, et al. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep. 2022;39(8):110856. doi:10.1016/j.celrep.2022.110856
   PubMed Web of Science ®Google Scholar
• Franz KM, Neidermyer WJ, Tan Y-J, Whelan SPJ, Kagan JC. STING-dependent translation inhibition restricts RNA virus replication. Proc Natl Acad Sci U S A. 2018;115(9):E2058–E2067. doi:10.1073/pnas.1716937115
   PubMed Web of Science ®Google Scholar
• Thim-uam A, Prabakaran T, Tansakul M, et al. STING mediates lupus via the activation of conventional dendritic cell maturation and plasmacytoid dendritic cell differentiation. iScience. 2020;23(9):101530. doi:10.1016/j.isci.2020.101530
   PubMed Web of Science ®Google Scholar
• Vieira R, Nascimento MS, Noronha IH, et al. STING signaling drives production of innate cytokines, generation of CD8+ T cells and enhanced protection against Trypanosoma cruzi infection. Front Immunol. 2022;12:775346. doi:10.3389/fimmu.2021.775346
   PubMed Web of Science ®Google Scholar
• Luo K, Li N, Ye W, Gao H, Luo X, Cheng B. Activation of Stimulation of Interferon Genes (STING) signal and cancer immunotherapy. Molecules. 2022;27(14):4638. doi:10.3390/molecules27144638
   PubMed Web of Science ®Google Scholar
• Corrales L, Glickman Laura H, McWhirter Sarah M, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 2015;11(7):1018–1030. doi:10.1016/j.celrep.2015.04.031
   PubMed Web of Science ®Google Scholar
• Cerón S, North BJ, Taylor SA, Leib DA. The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease. Virology. 2019;529:23–28. doi:10.1016/j.virol.2019.01.006
   PubMed Web of Science ®Google Scholar
• Shen H, Jin L, Zheng Q, et al. Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment. Bioact Mater. 2023;24:37–53. doi:10.1016/j.bioactmat.2022.12.001
   PubMed Web of Science ®Google Scholar
• Tansakul M, Thim-uam A, Saethang T, et al. Deficiency of STING promotes collagen-specific antibody production and B cell survival in collagen-induced arthritis. Front Immunol. 2020;11:1101. doi:10.3389/fimmu.2020.01101
   PubMed Web of Science ®Google Scholar
• Papinska J, Bagavant H, Gmyrek GB, et al. Activation of Stimulator of Interferon Genes (STING) and sjögren syndrome. J Dent Res. 2018;97(8):893–900. doi:10.1177/0022034518760855
   PubMed Web of Science ®Google Scholar
• Domizio JD, Gulen MF, Saidoune F, et al. The cGAS–STING pathway drives type I IFN immunopathology in COVID-19. Nature. 2022;603(7899):145–151. doi:10.1038/s41586-022-04421-w
   PubMed Web of Science ®Google Scholar
• Li M, Ferretti M, Ying B, et al. Pharmacological activation of STING blocks SARS-CoV-2 infection. Sci Immunol. 2021;6(59):eabi9007. doi:10.1126/sciimmunol.abi9007
   PubMed Web of Science ®Google Scholar
• Banjanac M, Munić Kos V, Nujić K, et al. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. 2012;66(4):357–362. doi:10.1016/j.phrs.2012.06.011
   PubMed Web of Science ®Google Scholar
• Menzel M, Akbarshahi H, Uller L. Azithromycin exhibits interferon-inducing properties in an experimental mouse model of asthma exacerbation. Eur Respir J. 2015;46(suppl 59):PA5095.
   Google Scholar
• Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Interferon-β up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol. 2004;138(3):499–506. doi:10.1111/j.1365-2249.2004.02624.x
   PubMed Web of Science ®Google Scholar
• Bauvois B, Nguyen J, Tang R, Billard C, Kolb JP. Types I and II interferons upregulate the costimulatory CD80 molecule in monocytes via interferon regulatory factor-1. Biochem Pharmacol. 2009;78(5):514–522. doi:10.1016/j.bcp.2009.05.005
   PubMed Web of Science ®Google Scholar
• Karimi Y, Giles EC, Vahedi F, et al. IFN-β signalling regulates RAW 264.7 macrophage activation, cytokine production, and killing activity. Innate Immun. 2020;26(3):172–182. doi:10.1177/1753425919878839
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103. doi:10.1038/nri3787
   PubMed Web of Science ®Google Scholar
• Fulton SA, Reba SM, Pai RK, et al. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect Immun. 2004;72(4):2101–2110. doi:10.1128/IAI.72.4.2101-2110.2004
   PubMed Web of Science ®Google Scholar
• Takaoka A, Mitani Y, Suemori H, et al. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science. 2000;288(5475):2357–2360. doi:10.1126/science.288.5475.2357
   PubMed Web of Science ®Google Scholar
• Iwamoto S, Kumamoto T, Azuma E, et al. The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells. Clin Exp Immunol. 2011;166(3):385–392. doi:10.1111/j.1365-2249.2011.04480.x
   PubMed Web of Science ®Google Scholar
• Huang S-W, Chen Y-J, Wang S-T, et al. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice. J Dermatol Sci. 2016;84(1):59–70. doi:10.1016/j.jdermsci.2016.07.007
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang S, Jeon R, et al. Interferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity. EBioMedicine. 2018;30:303–316. doi:10.1016/j.ebiom.2018.02.009
   PubMed Web of Science ®Google Scholar
• Xie C, Liu C, Wu B, et al. Effects of IRF1 and IFN-β interaction on the M1 polarization of macrophages and its antitumor function. Int J Mol Med. 2016;38(1):148–160. doi:10.3892/ijmm.2016.2583
   PubMed Web of Science ®Google Scholar
• Zhu X, Guo Q, Zou J, et al. MiR-19a-3p suppresses M1 macrophage polarization by inhibiting STAT1/IRF1 pathway. Front Pharmacol. 2021;12:614044. doi:10.3389/fphar.2021.614044
   PubMed Web of Science ®Google Scholar
• Cohen Katsenelson K, Stender JD, Kawashima AT, et al. PHLPP1 counter-regulates STAT1-mediated inflammatory signaling. eLife. 2019;8:e48609. doi:10.7554/eLife.48609
   PubMed Web of Science ®Google Scholar
• Tsai WC, Hershenson MB, Zhou Y, Sajjan U. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflamm Res. 2009;58(8):491–501. doi:10.1007/s00011-009-0015-9
   PubMed Web of Science ®Google Scholar
• Menzel M, Akbarshahi H, Tufvesson E, Persson C, Bjermer L, Uller L. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017;8(19):31601–31611. doi:10.18632/oncotarget.16364
   PubMedGoogle Scholar
• Schögler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015;45(2):428–439. doi:10.1183/09031936.00102014
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32(1):513–545. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Mosallanejad K, Kagan JC. Control of innate immunity by the cGAS-STING pathway. Immunol Cell Biol. 2022;100(6):409–423. doi:10.1111/imcb.12555
   PubMed Web of Science ®Google Scholar
• Nujić K, Banjanac M, Munić V, Polančec D, Eraković Haber V. Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell Immunol. 2012;279(1):78–86. doi:10.1016/j.cellimm.2012.09.007
   PubMed Web of Science ®Google Scholar
• Toriyama K, Takano N, Kokuba H, et al. Azithromycin enhances the cytotoxicity of DNA-damaging drugs via lysosomal membrane permeabilization in lung cancer cells. Cancer Sci. 2021;112(8):3324–3337. doi:10.1111/cas.14992
   PubMed Web of Science ®Google Scholar
• Tian A-L, Wu Q, Liu P, et al. Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. Cell Death Dis. 2021;12(1):6. doi:10.1038/s41419-020-03324-w
   PubMed Web of Science ®Google Scholar
• Kim J, Kim H-S, Chung JH. Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp Mol Med. 2023;55(3):510–519. doi:10.1038/s12276-023-00965-7
   PubMed Web of Science ®Google Scholar